Zydus Lifesciences names Nitin D Parekh as President (Special Projects)
Ahmedabad: Zydus Lifesciences has announced the appointment of Nitin D. Parekh as President (Special Projects), with effect from September 8, 2025. "This is to inform that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors of Zydus Lifesciences Limited have approved the appointment of Mr. Nitin D. Parekh as a President (Special Projects), who shall form part of Senior Management," the company stated in a BSE filing. The company stated that the appointment is aimed at strengthening its management team in view of the increase in its size and scale of business operations and the complexity of its business. Nitin Parekh, aged 64 years, is a top-notch finance leader with brilliant academic track record and ~4 decades of professional & leadership experience across finance, strategy, legal & IT and across pharma & textiles. He has razor-sharp commercial acumen combined with expertise on wide-ranging topics including M&A, negotiations & deals structuring, capital structure design, corporate and business strategy, finance, and general management strategies. Out of 40+ years professional experience, he has worked for 16+ years with Zydus Lifesciences Limited in the capacity of a Chief Financial Officer. He has multiple educational qualifications including CA, CFA and MBA from Indian Institute of Management, Ahmedabad. Parekh has received several national level awards, including Best CFO of Healthcare & Pharma (2025) from Assocham, Hall of Fame (2024) from CFO Collective, Excellence in M&A from CII, Best CFO of India-Large Enterprises from Businessworld (2021) and Best CFO of Healthcare sector in India from ICAI for 2012 and 2017. Zydus Lifesciences Ltd. is a global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.